Serial EntrepreneurAbout
We gets into the brain by non-invasively opening the blood-brain barrier — without redesigning the molecule. The company's platform uses a non-invasive stimulation device to temporarily and reversibly open the BBB, enabling enhanced delivery of already-approved CNS assets, repurposing of systemic drugs for CNS indications, and revival of failed assets shelved due to delivery challenges rather than efficacy.
Traction & Metrics
Fundraising
$1M
Previous Round
Products
Apertum BBB Opening Platform
A non-invasive, outpatient device that temporarily opens the blood-brain barrier (BBB) to enable therapeutic delivery of drugs, biologics, and gene therapies into the brain — without requiring redesign of the molecule. The 4-step outpatient procedure (45-minute non-invasive BBB priming, standard IV infusion, enhanced delivery, and same-day discharge) requires no sedation, shaving, or surgery. The platform has demonstrated delivery of payloads ranging from small molecules (55 kDa) to antibodies (150 kDa) and viral vectors (5,300 kDa) — all above the natural BBB cutoff of 0.4 kDa that blocks 98% of CNS drugs. Validated across rodent, porcine, and non-human primate models, with NHP data showing 6x (up to ~800% of wild-type) ARSA enzyme activity in the substantia nigra following AAV delivery. Designed with a compact, TMS-comparable footprint and adaptable coil architecture for focal or whole-brain targeting, suitable for small outpatient clinics.
Click to read more
Updates
Nominated to present at TechCrunch Battlefield 2026
https://techcrunch.com/2026/08/20/the-2026-startup-battlefield-200-is-here-see-who-made-the-cut/
